Tufts Medical Center

A 36-item short-form (SF-36) was constructed to survey health status in the Medical Outcomes Study. The SF-36 was designed for use in clinical practice and research, health policy evaluations, and general population surveys. The SF-36 includes one multi-item scale that assesses eight health concepts: 1) limitations in physical activities because of health problems; 2) limitations in social activities because of physical or emotional problems; 3) limitations in usual role activities because of physical health problems; 4) bodily pain; 5) general mental health (psychological distress and well-being); 6) limitations in usual role activities because of emotional problems; 7) vitality (energy and fatigue); and 8) general health perceptions. The survey was constructed for self-administration by persons 14 years of age and older, and for administration by a trained interviewer in person or by telephone. The history of the development of the SF-36, the origin of specific items, and the logic underlying their selection are summarized. The content and features of the SF-36 are compared with the 20-item Medical Outcomes Study short-form.

The revised criteria for the classification of rheumatoid arthritis (RA) were formulated from a computerized analysis of 262 contemporary, consecutively studied patients with RA and 262 control subjects with rheumatic diseases other than RA (non-RA). The new criteria are as follows: 1) morning stiffness in and around joints lasting at least 1 hour before maximal improvement; 2) soft tissue swelling (arthritis) of 3 or more joint areas observed by a physician; 3) swelling (arthritis) of the proximal interphalangeal, metacarpophalangeal, or wrist joints; 4) symmetric swelling (arthritis); 5) rheumatoid nodules; 6) the presence of rheumatoid factor; and 7) radiographic erosions and/or periarticular osteopenia in hand and/or wrist joints. Criteria 1 through 4 must have been present for at least 6 weeks. Rheumatoid arthritis is defined by the presence of 4 or more criteria, and no further qualifications (classic, definite, or probable) or list of exclusions are required. In addition, a "classification tree" schema is presented which performs equally as well as the traditional (4 of 7) format. The new criteria demonstrated 91-94% sensitivity and 89% specificity for RA when compared with non-RA rheumatic disease control subjects.

Regression methods were used to select and score 12 items from the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36) to reproduce the Physical Component Summary and Mental Component Summary scales in the general US population (n=2,333). The resulting 12-item short-form (SF-12) achieved multiple R squares of 0.911 and 0.918 in predictions of the SF-36 Physical Component Summary and SF-36 Mental Component Summary scores, respectively. Scoring algorithms from the general population used to score 12-item versions of the two components (Physical Components Summary and Mental Component Summary) achieved R squares of 0.905 with the SF-36 Physical Component Summary and 0.938 with SF-36 Mental Component Summary when cross-validated in the Medical Outcomes Study. Test-retest (2-week)correlations of 0.89 and 0.76 were observed for the 12-item Physical Component Summary and the 12-item Mental Component Summary, respectively, in the general US population (n=232). Twenty cross-sectional and longitudinal tests of empirical validity previously published for the 36-item short-form scales and summary measures were replicated for the 12-item Physical Component Summary and the 12-item Mental Component Summary, including comparisons between patient groups known to differ or to change in terms of the presence and seriousness of physical and mental conditions, acute symptoms, age and aging, self-reported 1-year changes in health, and recovery for depression. In 14 validity tests involving physical criteria, relative validity estimates for the 12-item Physical Component Summary ranged from 0.43 to 0.93 (median=0.67) in comparison with the best 36-item short-form scale. Relative validity estimates for the 12-item Mental Component Summary in 6 tests involving mental criteria ranged from 0.60 to 107 (median=0.97) in relation to the best 36-item short-form scale. Average scores for the 2 summary measures, and those for most scales in the 8-scale profile based on the 12-item short-form, closely mirrored those for the 36-item short-form, although standard errors were nearly always larger for the 12-item short-form.

BACKGROUND: Serum creatinine concentration is widely used as an index of renal function, but this concentration is affected by factors other than glomerular filtration rate (GFR). OBJECTIVE: To develop an equation to predict GFR from serum creatinine concentration and other factors. DESIGN: Cross-sectional study of GFR, creatinine clearance, serum creatinine concentration, and demographic and clinical characteristics in patients with chronic renal disease. PATIENTS: 1628 patients enrolled in the baseline period of the Modification of Diet in Renal Disease (MDRD) Study, of whom 1070 were randomly selected as the training sample; the remaining 558 patients constituted the validation sample. METHODS: The prediction equation was developed by stepwise regression applied to the training sample. The equation was then tested and compared with other prediction equations in the validation sample. RESULTS: To simplify prediction of GFR, the equation included only demographic and serum variables. Independent factors associated with a lower GFR included a higher serum creatinine concentration, older age, female sex, nonblack ethnicity, higher serum urea nitrogen levels, and lower serum albumin levels (P < 0.001 for all factors). The multiple regression model explained 90.3% of the variance in the logarithm of GFR in the validation sample. Measured creatinine clearance overestimated GFR by 19%, and creatinine clearance predicted by the Cockcroft-Gault formula overestimated GFR by 16%. After adjustment for this overestimation, the percentage of variance of the logarithm of GFR predicted by measured creatinine clearance or the Cockcroft-Gault formula was 86.6% and 84.2%, respectively. CONCLUSION: The equation developed from the MDRD Study provided a more accurate estimate of GFR in our study group than measured creatinine clearance or other commonly used equations.

Cardiovascular diseases (CVDs), principally ischemic heart disease (IHD) and stroke, are the leading cause of global mortality and a major contributor to disability. This paper reviews the magnitude of total CVD burden, including 13 underlying causes of cardiovascular death and 9 related risk factors, using estimates from the Global Burden of Disease (GBD) Study 2019. GBD, an ongoing multinational collaboration to provide comparable and consistent estimates of population health over time, used all available population-level data sources on incidence, prevalence, case fatality, mortality, and health risks to produce estimates for 204 countries and territories from 1990 to 2019. Prevalent cases of total CVD nearly doubled from 271 million (95% uncertainty interval [UI]: 257 to 285 million) in 1990 to 523 million (95% UI: 497 to 550 million) in 2019, and the number of CVD deaths steadily increased from 12.1 million (95% UI:11.4 to 12.6 million) in 1990, reaching 18.6 million (95% UI: 17.1 to 19.7 million) in 2019. The global trends for disability-adjusted life years (DALYs) and years of life lost also increased significantly, and years lived with disability doubled from 17.7 million (95% UI: 12.9 to 22.5 million) to 34.4 million (95% UI:24.9 to 43.6 million) over that period. The total number of DALYs due to IHD has risen steadily since 1990, reaching 182 million (95% UI: 170 to 194 million) DALYs, 9.14 million (95% UI: 8.40 to 9.74 million) deaths in the year 2019, and 197 million (95% UI: 178 to 220 million) prevalent cases of IHD in 2019. The total number of DALYs due to stroke has risen steadily since 1990, reaching 143 million (95% UI: 133 to 153 million) DALYs, 6.55 million (95% UI: 6.00 to 7.02 million) deaths in the year 2019, and 101 million (95% UI: 93.2 to 111 million) prevalent cases of stroke in 2019. Cardiovascular diseases remain the leading cause of disease burden in the world. CVD burden continues its decades-long rise for almost all countries outside high-income countries, and alarmingly, the age-standardized rate of CVD has begun to rise in some locations where it was previously declining in high-income countries. There is an urgent need to focus on implementing existing cost-effective policies and interventions if the world is to meet the targets for Sustainable Development Goal 3 and achieve a 30% reduction in premature mortality due to noncommunicable diseases.

Funnel plots, and tests for funnel plot asymmetry, have been widely used to examine bias in the results of meta-analyses. Funnel plot asymmetry should not be equated with publication bias, because it has a number of other possible causes. This article describes how to interpret funnel plot asymmetry, recommends appropriate tests, and explains the implications for choice of meta-analysis model

Normal somatic cells invariably enter a state of irreversibly arrested growth and altered function after a finite number of divisions. This process, termed replicative senescence, is thought to be a tumor-suppressive mechanism and an underlying cause of aging. There is ample evidence that escape from senescence, or immortality, is important for malignant transformation. By contrast, the role of replicative senescence in organismic aging is controversial. Studies on cells cultured from donors of different ages, genetic backgrounds, or species suggest that senescence occurs in vivo and that organismic lifespan and cell replicative lifespan are under common genetic control. However, senescent cells cannot be distinguished from quiescent or terminally differentiated cells in tissues. Thus, evidence that senescent cells exist and accumulate with age in vivo is lacking. We show that several human cells express a beta-galactosidase, histochemically detectable at pH 6, upon senescence in culture. This marker was expressed by senescent, but not presenescent, fibroblasts and keratinocytes but was absent from quiescent fibroblasts and terminally differentiated keratinocytes. It was also absent from immortal cells but was induced by genetic manipulations that reversed immortality. In skin samples from human donors of different age, there was an age-dependent increase in this marker in dermal fibroblasts and epidermal keratinocytes. This marker provides in situ evidence that senescent cells may exist and accumulate with age in vivo.

Cross-sectional data from the Medical Outcomes Study (MOS) were analyzed to test the validity of the MOS 36-Item Short-Form Health Survey (SF-36) scales as measures of physical and mental health constructs. Results from traditional psychometric and clinical tests of validity were compared. Principal components analysis was used to test for hypothesized physical and mental health dimensions. For purposes of clinical tests of validity, clinical criteria defined mutually exclusive adult patient groups differing in severity of medical and psychiatric conditions. Scales shown in the components analysis to primarily measure physical health (physical functioning and role limitations-physical) best distinguished groups differing in severity of chronic medical condition and had the most pure physical health interpretation. Scales shown to primarily measure mental health (mental health and role limitations-emotional) best distinguished groups differing in the presence and severity of psychiatric disorders and had the most pure mental health interpretation. The social functioning, vitality, and general health perceptions scales measured both physical and mental health components and, thus, had the most complex interpretation. These results are useful in establishing guidelines for the interpretation of each scale and in documenting the size of differences between clinical groups that should be considered very large.

The Infectious Diseases Society of America (IDSA) continues to view with concern the lean pipeline for novel therapeutics to treat drug-resistant infections, especially those caused by gram-negative pathogens. Infections now occur that are resistant to all current antibacterial options. Although the IDSA is encouraged by the prospect of success for some agents currently in preclinical development, there is an urgent, immediate need for new agents with activity against these panresistant organisms. There is no evidence that this need will be met in the foreseeable future. Furthermore, we remain concerned that the infrastructure for discovering and developing new antibacterials continues to stagnate, thereby risking the future pipeline of antibacterial drugs. The IDSA proposed solutions in its 2004 policy report, "Bad Bugs, No Drugs: As Antibiotic R&D Stagnates, a Public Health Crisis Brews," and recently issued a "Call to Action" to provide an update on the scope of the problem and the proposed solutions. A primary objective of these periodic reports is to encourage a community and legislative response to establish greater financial parity between the antimicrobial development and the development of other drugs. Although recent actions of the Food and Drug Administration and the 110th US Congress present a glimmer of hope, significant uncertainly remains. Now, more than ever, it is essential to create a robust and sustainable antibacterial research and development infrastructure--one that can respond to current antibacterial resistance now and anticipate evolving resistance. This challenge requires that industry, academia, the National Institutes of Health, the Food and Drug Administration, the Centers for Disease Control and Prevention, the US Department of Defense, and the new Biomedical Advanced Research and Development Authority at the Department of Health and Human Services work productively together. This report provides an update on potentially effective antibacterial drugs in the late-stage development pipeline, in the hope of encouraging such collaborative action.

BACKGROUND: The combined thickness of the intima and media of the carotid artery is associated with the prevalence of cardiovascular disease. We studied the associations between the thickness of the carotid-artery intima and media and the incidence of new myocardial infarction or stroke in persons without clinical cardiovascular disease. METHODS: Noninvasive measurements of the intima and media of the common and internal carotid artery were made with high-resolution ultrasonography in 5858 subjects 65 years of age or older. Cardiovascular events (new myocardial infarction or stroke) served as outcome variables in subjects without clinical cardiovascular disease (4476 subjects) over a median follow-up period of 6.2 years. RESULTS: The incidence of cardiovascular events correlated with measurements of carotid-artery intima-media thickness. The relative risk of myocardial infarction or stroke increased with intima-media thickness (P<0.001). The relative risk of myocardial infarction or stroke (adjusted for age and sex) for the quintile with the highest thickness as compared with the lowest quintile was 3.87 (95 percent confidence interval, 2.72 to 5.51). The association between cardiovascular events and intima-media thickness remained significant after adjustment for traditional risk factors, showing increasing risks for each quintile of combined intima-media thickness, from the second quintile (relative risk, 1.54; 95 percent confidence interval, 1.04 to 2.28), to the third (relative risk, 1.84; 95 percent confidence interval, 1.26 to 2.67), fourth (relative risk, 2.01; 95 percent confidence interval, 1.38 to 2.91), and fifth (relative risk, 3.15; 95 percent confidence interval, 2.19 to 4.52). The results of separate analyses of myocardial infarction and stroke paralleled those for the combined end point. CONCLUSIONS: Increases in the thickness of the intima and media of the carotid artery, as measured noninvasively by ultrasonography, are directly associated with an increased risk of myocardial infarction and stroke in older adults without a history of cardiovascular disease.

Chronic kidney disease is a worldwide public health problem with an increasing incidence and prevalence, poor outcomes, and high cost. Outcomes of chronic kidney disease include not only kidney failure but also complications of decreased kidney function and cardiovascular disease. Current evidence suggests that some of these adverse outcomes can be prevented or delayed by early detection and treatment. Unfortunately, chronic kidney disease is underdiagnosed and undertreated, in part as a result of lack of agreement on a definition and classification of its stages of progression. Recent clinical practice guidelines by the National Kidney Foundation 1) define chronic kidney disease and classify its stages, regardless of underlying cause, 2) evaluate laboratory measurements for the clinical assessment of kidney disease, 3) associate the level of kidney function with complications of chronic kidney disease, and 4) stratify the risk for loss of kidney function and development of cardiovascular disease. The guidelines were developed by using an approach based on the procedure outlined by the Agency for Healthcare Research and Quality. This paper presents the definition and five-stage classification system of chronic kidney disease and summarizes the major recommendations on early detection in adults. Recommendations include identifying persons at increased risk (those with diabetes, those with hypertension, those with a family history of chronic kidney disease, those older than 60 years of age, or those with U.S. racial or ethnic minority status), detecting kidney damage by measuring the albumin-creatinine ratio in untimed ("spot") urine specimens, and estimating the glomerular filtration rate from serum creatinine measurements by using prediction equations. Because of the high prevalence of early stages of chronic kidney disease in the general population (approximately 11% of adults), this information is particularly important for general internists and specialists.

This review of Alzheimer's disease assembles a variety of findings relevant to the mechanism of the disease and ties them together using the current understanding of the basis of the loss of cognition: the accumulation of misfolded proteins, which cause oxidative and inflammatory damage to the brain and, ultimately, synaptic dysfunction.

The widespread use of standardized health surveys is predicated on the largely untested assumption that scales constructed from those surveys will satisfy minimum psychometric requirements across diverse population groups. Data from the Medical Outcomes Study (MOS) were used to evaluate data completeness and quality, test scaling assumptions, and estimate internal-consistency reliability for the eight scales constructed from the MOS SF-36 Health Survey. Analyses were conducted among 3,445 patients and were replicated across 24 subgroups differing in sociodemographic characteristics, diagnosis, and disease severity. For each scale, item-completion rates were high across all groups (88% to 95%), but tended to be somewhat lower among the elderly, those with less than a high school education, and those in poverty. On average, surveys were complete enough to compute scales scores for more than 96% of the sample. Across patient groups, all scales passed tests for item-internal consistency (97% passed) and item-discriminant validity (92% passed). Reliability coefficients ranged from a low of 0.65 to a high of 0.94 across scales (median = 0.85) and varied somewhat across patient subgroups. Floor effects were negligible except for the two role disability scales. Noteworthy ceiling effects were observed for both role disability scales and the social functioning scale. These findings support the use of the SF-36 survey across the diverse populations studied and identify population groups in which use of standardized health status measures may or may not be problematic.

Background Childhood obesity increases the risk of obesity in adulthood, but how parental obesity affects the chances of a child's becoming an obese adult is unknown. We investigated the risk of obesity in young adulthood associated with both obesity in childhood and obesity in one or both parents.

Potential conflict of interest: Dr. Hwang received grants from Merck and Gilead. Dr. Chang advises Arbutus. Dr. Lok received grants from Gilead and Bristol‐Myers Squibb. Dr. Jonas consults for Gilead and received grants from Bristol‐Myers Squibb and Roche. Dr. Brown consults and received grants from Gilead. Dr. Bzowej received grants from Gilead, Allergan and Cirius. Dr. Terrault received grants from Gilead and Bristol‐Myers Quibb. Dr. Wong is a member of the United States Preventive Services Task Force (USPSTF). This article does not necessarily represent the views and policies of the USPSTF. The funding for the development of this Practice Guidance was provided by the American Association for the Study of Liver Diseases. This practice guidance was approved by the American Association for the Study of Liver Diseases on December 4, 2017. Purpose and Scope of the Guidance This AASLD 2018 Hepatitis B Guidance is intended to complement the AASLD 2016 Practice Guidelines for Treatment of Chronic Hepatitis B1 and update the previous hepatitis B virus (HBV) guidelines from 2009. The 2018 updated guidance on chronic hepatitis B (CHB) includes (1) updates on treatment since the 2016 HBV guidelines (notably the use of tenofovir alafenamide) and guidance on (2) screening, counseling, and prevention; (3) specialized virological and serological tests; (4) monitoring of untreated patients; and (5) treatment of hepatitis B in special populations, including persons with viral coinfections, acute hepatitis B, recipients of immunosuppressive therapy, and transplant recipients. The AASLD 2018 Hepatitis B Guidance provides a data‐supported approach to screening, prevention, diagnosis, and clinical management of patients with hepatitis B. It differs from the published 2016 AASLD guidelines, which conducted systematic reviews and used a multidisciplinary panel of experts to rate the quality (level) of the evidence and the strength of each recommendation using the Grading of Recommendations Assessment, Development and Evaluation system in support of guideline recommendations.1 In contrast, this guidance document was developed by consensus of an expert panel, without formal systematic review or use of the Grading of Recommendations Assessment, Development, and Evaluation system. The 2018 guidance is based upon the following: (1) formal review and analysis of published literature on the topics; (2) World Health Organization guidance on prevention, care, and treatment of CHB5; and (3) the authors’ experience in acute hepatitis B and CHB. Intended for use by health care providers, this guidance identifies preferred approaches to the diagnostic, therapeutic, and preventive aspects of care for patients with CHB. As with clinical practice guidelines, it provides general guidance to optimize the care of the majority of patients and should not replace clinical judgement for a unique patient. This guidance does not seek to dictate a “one size fits all” approach for the management of CHB. Clinical considerations may justify a course of action that differs from this guidance. Interim Data Relevant to the AASLD 2018 Hepatitis B Guidance Since the publication of the 2016 AASLD Hepatitis B Guidelines, tenofovir alafenamide (TAF) has been approved for treatment of CHB in adults. TAF joins the list of preferred HBV therapies, along with entecavir, tenofovir disoproxil fumarate (TDF), and peginterferon (peg‐IFN; Tables 1 and 2)6 (section: Updated Recommendations on the Treatment of Patients With Chronic Hepatitis B). Additionally, studies on the use of TDF for prevention of mother‐to‐child transmission led to TDF being elevated to the level of preferred therapy in this setting (section 1C of Screening, Counseling, and Prevention of Hepatitis B). Table 1 - Approved Antiviral Therapies in Adults and Children Drug Dose in Adultsa Use in Childrena Pregnancy Categoryb Potential Side Effectsb Monitoring on Treatmentc Preferred Peg‐IFN‐α‐2a (adult) IFN‐α‐2b (children) 180 mcg weekly ≥1 year dose: 6 million IU/m2 three times weeklyd C Flu‐like symptoms, fatigue, mood disturbances, cytopenia, autoimmune disorders in adults, anorexia and weight loss in children Complete blood count (monthly to every 3 months) TSH (every 3 months) Clinical monitoring for autoimmune, ischemic, neuropsychiatric, and infectious complications Entecavir 0.5 mg dailye ≥2 years dose: weight‐based to 10‐30 kg; above 30 kg: 0.5 mg dailye C Lactic acidosis (decompensated cirrhosis only) Lactic acid levels if there is clinical concern Test for HIV before treatment initiation Tenofovir dipovoxil fumarate 300 mg daily ≥12 years B Nephropathy, Fanconi syndrome, osteomalacia, lactic acidosis Creatinine clearance at baseline If at risk for renal impairment, creatinine clearance, serum phosphate, urine glucose, and protein at least annually Consider bone density study at baseline and during treatment in patients with history of fracture or risks for osteopenia Lactic acid levels if there is clinical concern Test for HIV before treatment initiation Tenofovir alafenamide 25 mg daily — There are insufficient human data on use during pregnancy to inform a drug‐associated risk of birth defects and miscarriage. Lactic acidosis Lactic acid levels if clinical concern Assess serum creatinine, serum phosphorus, creatinine clearance, urine glucose, and urine protein before initiating and during therapy in all patients as clinically appropriate Test for HIV before treatment initiation Nonpreferred Lamivudine 100 mg daily ≥2 years dose: 3 mg/kg daily to max 100 mg C Pancreatitis Lactic acidosis Amylase if symptoms are present Lactic acid levels if there is clinical concern Test for HIV before treatment initiation Adefovir 10 mg daily ≥12 years C Acute renal failure Fanconi syndrome Lactic acidosis Creatinine clearance at baseline If at risk for renal impairment, creatinine clearance, serum phosphate, urine glucose, and urine protein at least annually Consider bone density study at baseline and during treatment in patients with history of fracture or risks for osteopenia Lactic acid levels if clinical concern Telbivudine 600 mg daily — B Creatine kinase elevation and myopathy Peripheral neuropathy Lactic acidosis Creatine kinase if symptoms are present Clinical evaluation if symptoms are present Lactic acid levels if there is clinical concern aDose adjustments are needed in patients with renal dysfunction.bIn 2015, the U.S. Food and Drug Administration replaced the pregnancy risk designation by letters A, B, C, D, and X with more specific language on pregnancy and This is being in and to TAF includes is not approved for children with chronic hepatitis B, is approved for treatment of chronic hepatitis may using this for children with chronic The of treatment in is is 1 mg daily if the is or if Table - of Approved Antiviral Therapies in Adults with Chronic Hepatitis B and Tenofovir Tenofovir to loss — — loss 3 years 1 Entecavir Tenofovir Tenofovir to loss 6 3 years 6 of of 3 years of years of for for and tenofovir disoproxil for tenofovir for for and tenofovir disoproxil for tenofovir by and for and is a that of to HBV TAF is more TDF in and the to more a to used with and renal and bone 3 of hepatitis B patients with to TAF 25 mg daily or TDF 300 mg daily in a with serum HBV in in loss in and hepatitis B loss in in the TAF and TDF that and serum HBV and and and in TAF and TDF a 3 of patients with to TAF 25 mg daily or TDF 300 mg daily in a in in the TAF and TDF in serum HBV in of TAF patients and of TDF with 1 The approved of TAF is 25 mg with needed creatinine clearance is In 3 TAF TDF in bone density and renal at of In the in the rate was for TAF the was in TDF patients In the in the rate was in TAF the for TDF patients was In and bone density the in bone density for TAF TDF was for patients and in patients In human virus TAF TDF therapy for to that TAF a on bone density and renal with patients on TAF TDF or treatment of renal complications data in patients are with to the on clinical as renal and fracture the of TAF with evidence of led to the preferred HBV for patients studies of from TDF to TAF from the HIV In studies of to a to TAF TDF treatment of an was with in renal the and bone studies that TAF has a TDF and in studies of to 1 Screening, Counseling, and Prevention of Hepatitis B The of the of hepatitis B. Chronic acute is by the of for at least 6 The of with of persons as as to and as In developed the is from or and in with HBV is by and and by by and children in In HBV is transmission the of chronic transmission in the United in children of not appropriate HBV at The majority of children and with CHB in the United States are or HBV the for The risk of chronic HBV acute from in of to in and children to in In persons are more to chronic HBV acute Table 3 at risk for CHB should for HBV and if and to hepatitis B should used for to hepatitis B for as as are for and to from previous HBV HBV does not to Table 3 - at for HBV in of or HBV of and and and and of and of and and and and and and persons not as an in with HBV with immunosuppressive therapy, including to and for or with elevated or of of or with renal including and to with chronic with and of are not in a during the previous 6 evaluation or treatment for a Health care and at risk for to blood or and of for to with or of HBV are the of blood or that of persons with are years of for with are should hepatitis B if Table - of for HBV Test Chronic hepatitis B and management needed HBV management or or immunosuppressive therapy HBV or HBV if if not from of or and not persons may for not may or may not with the on or the risk The of for and for a of to populations, the is previous to HBV the majority of persons from acute HBV in and to been with HBV for before In the the risk of or cirrhosis to HBV is In the persons are at risk of with an rate that to to with chronic HBV with levels more if are if are and are in with of HBV or HIV or hepatitis C virus with more specific may a in persons from with risk for HBV and more may the of HBV during the of acute hepatitis persons should for of to of the risk for HBV for in blood if in Since the the of has to in blood and in with HIV or to or immunosuppressive therapy are at risk for if HBV and should for The majority of for not HBV with specific to or to hepatitis B and HBV with a HBV a HBV does not levels of HBV in blood in an on the and of the used and HBV in the study the of patients an to HBV with the majority a to hepatitis B to persons without HBV for all in Table should HBV to HBV with to levels 3 or data that may the of using an with HBV the of hepatitis B transmission the clinical of the patient. persons are for for are at risk of HBV the risk or immunosuppressive are or in Screening, Counseling, and Prevention of Hepatitis B, all persons are for or without should at risk for HBV in this Guidance on for Hepatitis B should using and is in all persons in with a of persons not as in with HBV persons immunosuppressive therapy, and the in Table persons should for to is not is an in patients HIV are to or and immunosuppressive or renal and in blood if Screening, Counseling, and Prevention of Hepatitis B, B, Patients with chronic HBV should and prevention of transmission as as the of specific been to on the of CHB syndrome and to of more of for and more for are with risk of cirrhosis and the risk of of are the approach is to or with CHB should hepatitis if not persons should transmission to Table of risk of HBV and should if for HBV serological or not been or not the should of HBV from health care to patients has been to in persons with CHB are the for and Prevention that should seek and from an expert review If serum HBV therapy is and of is if serum HBV is to and that Since the U.S. of has that it is for and to are to special to for children in the in and Table - Recommendations for Prevention of of HBV to and Use during if is not or is not or and blood with or Children and Adults in all including not from or and should not from children and and Guidance on of persons should prevention of transmission of HBV to and are should not from or practice hepatitis B. and of are to seek and from an expert review panel at should not if serum level may if level is and special are for children in as and are to or use of is in of weight and treatment of including of and are to development of syndrome and Guidance on of and or for is not in patients HIV or are to therapy or immunosuppressive are without are not at risk of transmission of or to are for and are from an with with risk for HBV should the of hepatitis B are for and risk for hepatitis B are not for are HIV or should for with CHB should to with the prevention of mother‐to‐child Hepatitis B and HBV should to Antiviral therapy in the is for with serum HBV of hepatitis with or without the of to been It has been that the in levels of the is to the therapy that has been used to the are and of acute failure been in the therapy from to not in the AASLD guideline recommendation that therapy for prevention of mother‐to‐child transmission at the of or to previous systematic review of therapy in the a in transmission of with or TDF is the preferred to and for with the of TDF treatment in the in risk of mother‐to‐child transmission of hepatitis B with TDF in with a level of HBV kinase levels more in untreated in as clinically studies in the of or data on bone from studies of therapy in a previous study of to bone the study at years of during as the risk of HBV in the is studies including and that the risk of HBV transmission by is more the risk of mother‐to‐child transmission of HBV was in with a level with not the risk of mother‐to‐child transmission the of in not clinical studies support the of during HBV is and during In of the to as without the of has been to and in Chronic HBV does not the of pregnancy the has cirrhosis or care is to the and to that the and HBV of Guidance on of in Pregnancy HBV is in and are not to or with HBV should this as during pregnancy should to care for HBV or for if and of for for HBV therapy should without HBV in the should treatment to mother‐to‐child are not on therapy as as at or should for to 6 for hepatitis and should to for The risk of mother‐to‐child transmission of HBV with should in the risk of in with with cirrhosis should in and with TDF to of as during pregnancy should for HBV or and HBV if is not Recommendations for are in the for and Prevention and on is for at risk of as of of persons with chronic and including with of patients is that in are at a risk of to are not in if the is as studies that serological patients as persons on or with chronic including a is the 10 are to the a of and is are including with on or with use of a of has been to the of patients the level of the of HBV with or without is for of or to or This includes and should of are on the during which is the is to for and for The for and Prevention has updated guidelines for and for health care to is should of may of should and HBV of birth by the for at 1 of The should not before of HBV should used for or 6 Guidance for Prevention of of Hepatitis B With Chronic HBV HBV an and are as a at and 6 or without hepatitis at and to 30 by a at used for the hepatitis and B for a at and 1 has been approved for and of persons are for and should HBV of should and HBV at and the of should at of of persons with chronic HBV chronic and persons with should for to the the of to the a is with a used for including with of is annually for chronic or are not if of to in patients and are and of Chronic Hepatitis B The for CHB and clinical to HBV are in Table The of for at least 6 the of As HBV is not to the are to with chronic and viral clearance, to the development of cirrhosis and CHB is a and with CHB clinical with levels of serum HBV and HBV The levels of serum and HBV as as are of that inform for treatment initiation as as treatment of and levels are needed to treatment Additionally, of using or as are in and with treatment Table 6 - and for Chronic Hepatitis B Chronic Hepatitis B (CHB) present for HBV from to and levels are in and are in CHB. or elevated levels Liver chronic hepatitis with CHB present for levels are million or elevated Liver or and CHB present for HBV in CHB and in CHB or elevated levels Liver or chronic hepatitis with or and with or without CHB present for HBV levels Liver of or levels of HBV loss of HBV in or patients immunosuppressive therapy for a a in HBV to baseline an level of HBV a baseline is and from to for patients Hepatitis times baseline and HBV and hepatitis loss of in a was loss of and of in a was and of in a was loss of in a was with levels and of clinical or evidence of viral in serum HBV from during treatment in a an virological and is for management of persons without cirrhosis are or of for in are to for and for of for of for and 25 for is to management of for in are to for and for of management of a for of for and 25 for is in of the been This to a elevation is the for of in the of treatment that the elevation may to as or 3 in of Chronic Hepatitis B of serum HBV is a in the evaluation of patients with CHB and in the of the of used in clinical practice with a of and a to patients with CHB levels that may from to monitoring of levels is more in and in the for patients with CHB levels and with CHB levels with levels in with CHB in CHB. The is an which the of chronic and been in patients with the of levels in the of of and of treatment HBV of HBV been The of HBV HBV been in the United with A, B, and C being HBV may an in the of as as to is with of and loss with from that HBV B is with at an more a rate of to and a rate of development with from that on in persons with HBV C in with HBV A, B, D, or In a of has been in persons with C or in with the The to led to development of and to and it that from as a for viral levels by in and by of or with The levels of are in patients In and HBV CHB. the of with to levels been with to cirrhosis and clearance in patients with a viral treatment of and provides a at in of for and for the of at that loss or HBV treatment In of the patients with B and C at and treatment of of the patients and of HBV at a treatment as by a level treatment of a in loss of and level with a 3 years or more of Hepatitis B in patients are patients on therapy, the of is virological which is as a in serum HBV from during treatment in a an virological with that during to a in serum HBV that may with in specific in the The and an level Guidance on Use of and is to treatment including initiation of treatment and evaluation of a to in patients is not for the or of patients with CHB. HBV in patients being for therapy, that and B are with of loss C and D, it is not for or of patients with CHB. for viral in patients is not in patients with treatment with on therapy, or experience virological during of Patients on Antiviral Treatment Patients not for therapy monitoring to the for therapy the AASLD 2016 HBV HBV patients should at to monitoring should levels Patients with with levels a to of elevated levels times the of for and for should for Liver should in patients with or elevated in patients been with HBV from a Patients with or or for may used in of to for of Liver are more serum to or in or if levels of as by elevated are HBV patients should with every 3 during the year to that are in the and every If the level monitoring should more In for or evaluation for should that a with HBV may patients in the in which or levels are CHB and In and HBV CHB from CHB with a and of and more of the specific is CHB loss has been to at the rate of this does not at a In a study of patients with CHB in of loss 10 years and to 25 loss in to therapy, being more with with of to cirrhosis or patients of are present or the risk of if loss in patients years or in with cirrhosis or with or hepatitis virus of with of has been This is from in which and are Guidance for Monitoring Patients With Chronic HBV on Treatment that CHB is a persons are not treatment should to an for treatment has patients with should for at to If levels above along with HBV should more should every Patients are with levels and levels times the for for should to years and at a of Liver the of and If the or or or treatment is to are and or If treatment is Patients are with levels and elevated levels times the should to are years and at a of Liver the of and If the or or or treatment is to are and or If treatment is Patients are with and HBV should for and HBV every 3 during the year to CHB. and levels should at to If are a monitoring levels above the along with HBV should more (every In persons with HBV elevated of should not or or autoimmune with CHB should for loss of In persons and monitoring are should if the has a member with or a of years for and years for been with HBV from a for The AASLD 2018 Practice Guidelines on has been the as for and the and of are of The guideline for of persons at risk of with every 6 There was insufficient evidence for or the of every 6 to is not in is or is an is if the risk of is this all patients with cirrhosis patients without and history should with a risk of persons with or HIV and with this there is insufficient evidence to in children in children with cirrhosis or with a member with Guidance for in patients with cirrhosis should with with or without every 6 at risk for or years and years of persons with a member with a history of or persons with should with with or without every 6 There are insufficient data to for in it is to children and with or cirrhosis and with a member with using with or without every 6 persons at risk for are in is not with every 6 should 6 of Chronic HBV in As with with the treatment are to risk of to and including In the viral for by and If is treatment of should If HBV is treatment is by the HBV and levels treatment of virus may to in the of the and monitoring during and treatment is to for viral In the the treatment of for patients with HBV and was and for on the of and HBV with this a in serum HBV an and HBV in patients with HBV before treatment been with and therapy has been to levels in and to with HBV the of and failure are The majority of with elevated HBV and of In patients with cirrhosis or for HBV treatment HBV therapy should with or TAF are the preferred patients with chronic monitoring levels is with for and HBV if levels to or or HBV therapy should if there is evidence of HBV in HBV from for HBV and There are HBV or and approved patients with and more for and review of therapy before initiation of or HBV therapy is with Guidance for Treatment of Patients with HBV and patients should for using the treatment is for patients with HBV treatment is by and levels as the AASLD HBV guidelines for patients are at risk of and with therapy, and monitoring of HBV levels every during treatment and for 3 is in not treatment for patients the AASLD HBV patients with are at risk of with levels should at at the of and during with and for levels or to during treatment or The AASLD 2016 HBV Guidelines of persons at risk for including with HIV persons with and from of Additionally, patients with or HBV levels should for the of to the management of the if there is the to is The is and if this is it should by to of in and has been and the of the quality for by the World Health Organization has led to in Table - at of in with of and with with or HIV with or history of with elevated or with or HBV list is not The of treatment is the of which is by of levels and a in on patients with elevated of HBV and of the for or The of cirrhosis may treatment as is the in HBV are not in patients with or HBV patients with levels may including during treatment of and if the levels treatment with preferred or is of HBV may to which should a on The approved treatment of chronic hepatitis is is the of without in or Treatment as from to the virological The of with does not the of an virological with to of In the study of

BACKGROUND: Current equations for estimated glomerular filtration rate (eGFR) that use serum creatinine or cystatin C incorporate age, sex, and race to estimate measured GFR. However, race in eGFR equations is a social and not a biologic construct. METHODS: We developed new eGFR equations without race using data from two development data sets: 10 studies (8254 participants, 31.5% Black) for serum creatinine and 13 studies (5352 participants, 39.7% Black) for both serum creatinine and cystatin C. In a validation data set of 12 studies (4050 participants, 14.3% Black), we compared the accuracy of new eGFR equations to measured GFR. We projected the prevalence of chronic kidney disease (CKD) and GFR stages in a sample of U.S. adults, using current and new equations. RESULTS: ; 95% CI, 3.4 to 4.4). For all equations, 85% or more of the eGFRs for Blacks and non-Blacks were within 30% of measured GFR. New creatinine-cystatin C equations without race were more accurate than new creatinine equations, with smaller differences between race groups. As compared with the current creatinine equation, the new creatinine equations, but not the new creatinine-cystatin C equations, increased population estimates of CKD prevalence among Blacks and yielded similar or lower prevalence among non-Blacks. CONCLUSIONS: New eGFR equations that incorporate creatinine and cystatin C but omit race are more accurate and led to smaller differences between Black participants and non-Black participants than new equations without race with either creatinine or cystatin C alone. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases.).

BACKGROUND: Estimates of glomerular filtration rate (GFR) that are based on serum creatinine are routinely used; however, they are imprecise, potentially leading to the overdiagnosis of chronic kidney disease. Cystatin C is an alternative filtration marker for estimating GFR. METHODS: Using cross-sectional analyses, we developed estimating equations based on cystatin C alone and in combination with creatinine in diverse populations totaling 5352 participants from 13 studies. These equations were then validated in 1119 participants from 5 different studies in which GFR had been measured. Cystatin and creatinine assays were traceable to primary reference materials. RESULTS: Mean measured GFRs were 68 and 70 ml per minute per 1.73 m(2) of body-surface area in the development and validation data sets, respectively. In the validation data set, the creatinine-cystatin C equation performed better than equations that used creatinine or cystatin C alone. Bias was similar among the three equations, with a median difference between measured and estimated GFR of 3.9 ml per minute per 1.73 m(2) with the combined equation, as compared with 3.7 and 3.4 ml per minute per 1.73 m(2) with the creatinine equation and the cystatin C equation (P=0.07 and P=0.05), respectively. Precision was improved with the combined equation (interquartile range of the difference, 13.4 vs. 15.4 and 16.4 ml per minute per 1.73 m(2), respectively [P=0.001 and P<0.001]), and the results were more accurate (percentage of estimates that were >30% of measured GFR, 8.5 vs. 12.8 and 14.1, respectively [P<0.001 for both comparisons]). In participants whose estimated GFR based on creatinine was 45 to 74 ml per minute per 1.73 m(2), the combined equation improved the classification of measured GFR as either less than 60 ml per minute per 1.73 m(2) or greater than or equal to 60 ml per minute per 1.73 m(2) (net reclassification index, 19.4% [P<0.001]) and correctly reclassified 16.9% of those with an estimated GFR of 45 to 59 ml per minute per 1.73 m(2) as having a GFR of 60 ml or higher per minute per 1.73 m(2). CONCLUSIONS: The combined creatinine-cystatin C equation performed better than equations based on either of these markers alone and may be useful as a confirmatory test for chronic kidney disease. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases.).

UNLABELLED: This study predicts the burden of incident osteoporosis-related fractures and costs in the United States, by sex, age group, race/ethnicity, and fracture type, from 2005 to 2025. Total fractures were >2 million, costing nearly $17 billion in 2005. Men account for >25% of the burden. Rapid growth in the disease burden is projected among nonwhite populations. INTRODUCTION: The aging of the U.S. population will likely lead to greater prevalence of osteoporosis. Policy makers require precise projections of the disease burden by demographic subgroups and skeletal sites to effectively target osteoporosis intervention and treatment programs. MATERIALS AND METHODS: A state transition Markov decision model was used to estimate total incident fractures and costs by age, sex, race/ethnicity, and skeletal site for the U.S. population 50 years of age for 2005-2025. RESULTS: More than 2 million incident fractures at a cost of $17 billion are predicted for 2005. Total costs including prevalent fractures are more than $19 billion. Men account for 29% of fractures and 25% of costs. Total incident fractures by skeletal site were vertebral (27%), wrist (19%), hip (14%), pelvic (7%), and other (33%). Total costs by fracture type were vertebral (6%), hip (72%), wrist (3%), pelvic (5%), and other (14%). By 2025, annual fractures and costs are projected to rise by almost 50%. The most rapid growth is estimated for people 65-74 years of age, with an increase>87%. An increase of nearly 175% is projected for Hispanic and other subpopulations. CONCLUSIONS: Osteoporosis prevention, treatment, and education efforts should address all skeletal sites, not just hip and vertebral, and appropriate attention is warranted for men and diverse race/ethnicity subgroups.

OBJECTIVE: To update and expand the 2013 Clinical Practice Guidelines for the Management of Pain, Agitation, and Delirium in Adult Patients in the ICU. DESIGN: Thirty-two international experts, four methodologists, and four critical illness survivors met virtually at least monthly. All section groups gathered face-to-face at annual Society of Critical Care Medicine congresses; virtual connections included those unable to attend. A formal conflict of interest policy was developed a priori and enforced throughout the process. Teleconferences and electronic discussions among subgroups and whole panel were part of the guidelines' development. A general content review was completed face-to-face by all panel members in January 2017. METHODS: Content experts, methodologists, and ICU survivors were represented in each of the five sections of the guidelines: Pain, Agitation/sedation, Delirium, Immobility (mobilization/rehabilitation), and Sleep (disruption). Each section created Population, Intervention, Comparison, and Outcome, and nonactionable, descriptive questions based on perceived clinical relevance. The guideline group then voted their ranking, and patients prioritized their importance. For each Population, Intervention, Comparison, and Outcome question, sections searched the best available evidence, determined its quality, and formulated recommendations as "strong," "conditional," or "good" practice statements based on Grading of Recommendations Assessment, Development and Evaluation principles. In addition, evidence gaps and clinical caveats were explicitly identified. RESULTS: The Pain, Agitation/Sedation, Delirium, Immobility (mobilization/rehabilitation), and Sleep (disruption) panel issued 37 recommendations (three strong and 34 conditional), two good practice statements, and 32 ungraded, nonactionable statements. Three questions from the patient-centered prioritized question list remained without recommendation. CONCLUSIONS: We found substantial agreement among a large, interdisciplinary cohort of international experts regarding evidence supporting recommendations, and the remaining literature gaps in the assessment, prevention, and treatment of Pain, Agitation/sedation, Delirium, Immobility (mobilization/rehabilitation), and Sleep (disruption) in critically ill adults. Highlighting this evidence and the research needs will improve Pain, Agitation/sedation, Delirium, Immobility (mobilization/rehabilitation), and Sleep (disruption) management and provide the foundation for improved outcomes and science in this vulnerable population.

In some patients who are hospitalized for acute illness, we have noted a reversible syndrome of headache, altered mental functioning, seizures, and loss of vision associated with findings indicating predominantly posterior leukoencephalopathy on imaging studies. To elucidate this syndrome, we searched the log books listing computed tomographic (CT) and magnetic resonance imaging (MRI) studies performed at the New England Medical Center in Boston and Hôpital Sainte Anne in Paris; we found 15 such patients who were evaluated from 1988 through 1994.